Beijing, China · Founded 2018 · Privately Held (backing)
Developer of gene therapy drugs intended to treat rare diseases. GeneCradle is based in Beijing, China and was founded in 2018. Its last reported valuation was $288 million in Feb 2022. It has raised $61 million.
Last reported valuation
$287.8M
Oct 2026
Priced at
—
Total raised
$61.0M
Last round
—
Cap table — not yet on record
GeneCradle's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of GeneCradle with a free account
·Watch GeneCradle: the Monday email on marks, rounds and moves
